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Abstract
HPV infection is a causal agent in many epithelial cancers, yet our understanding of genetic
susceptibility to HPV infection and resultant cancer risk is limited. Epidermodysplasia Verru-
ciformis is a rare condition of extreme susceptibility to cutaneous HPV infection primarily at-
tributable to mutations in TMC6 and TMC8. Genetic variation in the TMC6/TMC8 region
has been linked to beta-type HPV infection and squamous cell carcinoma of the skin, cervi-
cal cancer, HPV persistence and progression to cervical cancer. Here, we have tested the
hypothesis that the common TMC8 SNP rs7208422 is associated with high-risk HPV infec-
tion and risk of head and neck squamous cell carcinoma (HNSCC). Seropositivity to the
HPV L1 protein (HPV16, 18, 11, 31, 33, 35, 45, 52, 58) was measured in 514 cases and 452
population-based controls. Genotype was significantly associated with seropositivity to
HPV18 L1 (OR TT vs AA = 0.48, 95% CI = 0.22–0.99) and borderline significantly associated
with HPV16 L1 (OR TT vs AA = 0.58, 95% CI = 0.22–1.17). There was a consistent inverse
association between TMC8 genotype and infection with other HPV types, including statisti-
cally significant associations for HPV31 and HPV52. Consistent with these results, the vari-
ant T genotype was associated with a reduced risk of HNSCC (ORAT: 0.63, 95% CI 0.45–
0.89, ORTT: 0.54, 95% CI 0.36–0.81), even among subjects seronegative for all HPV types
(ORAT: 0.71, 95% CI 0.45–1.11, ORTT: 0.54, 95% CI 0.31–0.93). Our data indicate that com-
mon genetic variation in TMC8 is associated with high-risk HPV infection and HNSCC
etiology.
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Introduction
Null mutations in TMC6 and TMC8 confer extreme susceptibility to infection with cutaneous
(beta-type) HPV. These genes encode EVER1 and EVER2 which form a heterodimer that in-
teracts with the zinc transporter molecule ZnT-1 to control zinc levels within the cell [1]. The
rare syndrome Epidermodysplasia Verrucciformis (EV) is associated with mutation in either of
these genes and is characterized by large numbers of flat-like lesions infected with beta-HPVs,
mainly HPV5 and HPV8 virus. Previously, we observed that genetic variation in TMC8 was as-
sociated with seropositivity to cutaneous (beta) HPV and increased risk of squamous cell skin
cancer (SCC) [2]. The observations from EV and skin cancer patients suggest that the TMC6
and TMC8 genes could be important factors for host protection from papillomaviruses. While
the complex of EVER proteins is known to regulate zinc homeostasis in keratinocytes, it has re-
cently been demonstrated that the TMC6/8 genes are also expressed at high levels in T-lympho-
cytes [3,4]. Therefore, genetic variation in the TMC6/8 genes may impact HPV infection and
cancer risk either directly by modulating HPV infection in epithelial cells, or indirectly through
immune surveillance.
Although common genetic variation in TMC8 has been associated with beta-HPV infection,
it is also possible that TMC8 genetic variation contributes to high-risk HPV infection and at-
tendant cancer risk (cervical, other anogenital, and head and neck malignancies). In fact, work
by Wang et al [5] using dense genotyping methodology identified a rare SNP in the TMC6/
TMC8 gene region as being associated with HPV16 persistence. A more recent study by Castro
et al [6], demonstrated that two common SNPs in the TMC6/TMC8 gene were associated with
cervical cancer (in the absence of other HPV measurements). Whether common variation in
this gene region confers susceptibility to high-risk HPV infection remains incompletely under-
stood. In addition, the role of this gene in other HPV-related cancers, such as oropharyngeal
cancer (rev in [7]), has not been tested. Here, we sought to determine whether the common
SNP rs7208422 in TMC8 is associated with seropositivity to high-risk HPV types and risk of
HNSCC.
Materials and Methods
Ethics Statement
Study protocols and materials for recruitment of cases and controls were approved by the Insti-
tutional Review Boards at the nine medical facilities and Brown University. Written informed
consent was obtained from all study subjects.
Study subjects
This population-based case-control study was conducted in Greater Boston, MA between De-
cember 1999 and December 2003 and has been previously described [8]. Cases were HNSCC
patients identified from head and neck clinics and departments of otolaryngology or radiation
oncology at nine medical facilities in the study area during the study period. Eligible cases were
residents in the study area aged 18 years or older and with a pathologically confirmed diagnosis
of HNSCC no more than 6 months before the time of patient contact. Patients with carcinoma
in situ, lip, salivary gland, or nasooropharyngeal cancer or recurrent HNSCC were excluded.
The cancer registry was queried to insure that all eligible cases in the area were identified.
HNSCC cases included diagnosis codes 141–146, 148, 149, and 161 according to International
Classification of Disease, Ninth Revision (ICD-9). Cases were further classified by site into oral
(ICD-9 codes 143–145), oropharygeal (ICD-9 codes 146, 148, 149), and laryngeal (ICD-9 code
161) disease. Controls were frequency-matched to cases on age (± 3 years), gender, and town
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of residence identified fromMassachusetts town books through systematic random selection.
The town book includes all the residents more than 17 years of age listed by street address and
precincts. A potential control of the same gender and age as the case was sought from this list,
alternating the search direction through the book starting at the case address.
Detection of antibodies by multiplex serology
Venous blood samples were obtained from cases and controls. Serum was separated within 12–
24 hr of blood drawing and samples were stored at -80°C. To detect antibodies against HPV, a
glutathione S-transferase (GST) capture enzyme-linked immunosorbent assay (ELISA) was
used, in combination with fluorescent bead technology, as described in detail previously
[9,10,11,12]. Briefly, full-length viral proteins fused with an N-terminal GST domain were ex-
pressed in E. coli bacteria. Glutathione cross-linked to casein was coupled to fluorescence-la-
beled polystyrene beads (SeroMAPMicrospheres, Luminex Corp., Austin, TX) and GST fusion
proteins were in situ affinity-purified on the beads directly in a one-step procedure. Each fusion
protein was bound to a spectrally distinct bead set. Fusion protein-loaded bead sets were mixed
and incubated with human sera. Antibodies bound to the beads via the viral antigens were de-
tected with biotinylated goat-anti-human IgG (H+L) secondary antibody and streptavidin-R-
phycoerythrin. A Luminex 100 analyzer (Luminex Corp., Austin, TX) was used to identify the
internal color of the individual beads and to quantify their reporter fluorescence (expressed as
median fluorescence intensity (MFI) of at least 100 beads per set per serum).
MFI values were dichotomized as antibody positive or negative. A standardized cut-off for
HPV16, 18, 31, 33, 35, 45, 52 and 58 L1 antibodies was defined earlier [13] and applied here.
Seropositivity cut-offs for HPV16 early proteins were determined using a similar algorithm for
serum samples of 117 female, HPV DNA negative, self-reported virgins from a cross-sectional
study among Korean students [13]. The mean plus 5 standard deviations was calculated, and
the resulting single cut-off was doubled to stringently separate seropositive and-negative reac-
tions (HPV 16 E6, 484 MFI; HPV 16 E7, 1096 MFI) [14].
TMC8 genotype detection
We collected data on a (A> T) coding SNP in exon 8, codon 306 of the TMC8 gene
(rs7208422), resulting in a change from asparagine to isoleucine. DNA was extracted from
buffy coat using Qiagen genomic DNA extraction kits. Genotyping of the TMC8 polymor-
phism was done using the Taqman allelic discrimination technique (Applied Biosystems, Fos-
ter City, CA), as previously published [2]. Known genotype controls were included for each
genotyping assay. For quality assessment, every tenth sample was an embedded duplicate, and
there was 100% concordance among QA genotypes.
Statistical analysis
Data analysis was restricted to Caucasian subjects with both TMC8 genotype and HPV serolo-
gy data. To estimate the associations between TMC8 genotype and HNSCC, we calculated odds
ratios (ORs) and 95% confidence intervals (CIs) from unconditional logistic regression models.
Models included the study matching factors gender and age, however the third matching pa-
rameter, town of residence, was not included in these unconditional regression models given
the number of towns represented. Risk models were also adjusted for smoking (pack-years)
and drinking (average drinks per week). We additionally performed the analysis stratified by
tumor site as well as by HPV16 serology status. To examine the relationship between TMC8 ge-
notype and HPV serologic markers, we used logistic regression with positive serology as the
TMC8, HPV Infection and Head and Neck Cancer Risk
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response variable and TMC8 genotype as an independent variable. All statistical analyzes were
performed using SAS9.1, and all statistical tests were two-sided.
Results
Among the 775 subjects, 361 were cases with HNSCC (148 oral cavity cancers, 148 oropharyn-
geal cancers, 65 laryngeal cancers) and 414 were control subjects (Table 1). There were no sig-
nificant differences in the distributions of age and gender between cases and controls (Table 1).
Most subjects were males (74%). Compared to controls, HNSCC cases were more likely to
smoke (P<0.001) and drink heavily (P<0.001), and had a higher prevalence of seropositivity
to HPV16 (P<0.0001), HPV18 (p<0.04), HPV11 (p<0.003), HPV31 (P<0.01), HPV35
(p<0.001), HPV52 (p<0.0003) and HPV58 (p<0.003) (Table 1).
We evaluated the association between genotype and HPV serology (Table 2); given the very
low seroprevalence among controls (Table 1), it was necessary to test this association using
data from all subjects. TMC8 genotype was associated with HPV18 seropositivity (ORAT: 0.65,
95% CI 0.38–1.11, ORTT: 0.48, 95% CI 0.24–0.99), with similar non-significant trends observed
for HPV16 (ORAT: 0.91, 95% CI 0.54–1.55, ORTT: 0.58, 95% CI 0.22–1.17), HPV31 (ORAT:
0.60, 95% CI 0.33–1.09, ORTT: 0.48, 95% CI 0.22–1.04), and HPV52 (ORAT: 0.25, 95% CI 0.09–
0.67, ORTT: 0.36, 95% CI 0.11–1.13). We further examined the association between genotype
Table 1. Demographic characteristics of cases and controls.
Characteristic Cases (n = 361) Controls (n = 414) P
Age (years) 59.7 ± 11.5 61.0 ± 11.6 0.11
Gender 0.77
Female 94 (26%) 103 (24.9%)
Male 267 (74%) 311 (75.1%)
Pack-years of tobacco use <0.0001
Never 62 (17.2%) 137 (33.1%)
0 to <20 60 (16.7%) 116 (28.0%)
> = 20 239 (66.2%) 161 (38.9%)
Alcohol consumption, average drinks per week <0.0001
<8 122 (37.9%) 239 (58.0%)
> = 8 200 (62.1%) 173 (42.0%)
Missing 39 2
HPV L1 serology Positive:Negative (%)
HPV16 70:291 (19%) 14:400 (3.4%) <0.0001
HPV18 43:318 (12%) 30:384 (7.2%) <0.04
HPV11 35:326 (9.7%) 17:397 (4.1%) <0.003
HPV31 37:324 (10.2%) 22:392 (5.3%) <0.01
HPV33 15:346 (4.2%) 9:405 (2.2%) <0.17
HPV35 33:328 (9.1%) 14:400 (3.3%) <0.001
HPV45 18:343 (5.0%) 12:402 (2.9%) <0.19
HPV52 19:342 (5.3%) 3:411 (0.7%) <0.0003
HPV58 20:341 (5.5%) 6:408 (1.4%) <0.003
Tumor sites
Oral 148 (41.0%)
Pharynx 148 (41.0%)
Larynx 65 (18.0%)
doi:10.1371/journal.pone.0123716.t001
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and serology among oropharyngeal cancer cases; similar OR’s were observed, but with statisti-
cal imprecision (data not shown).
TMC8 genotype was also associated with a reduced risk of all types of HNSCC (Table 3).
Compared with TMC8 AA genotype, AT and TT genotypes were inversely associated with
HNSCC (OR = 0.63; 95% CI: 0.45–0.89 and OR = 0.4954; 95% CI: 0.36–0.81 respectively).
These findings were consistent across anatomic sites of HNSCC (Table 3). To determine
whether the genotype association was independent of HPV serology, we conducted subgroup
analysis among subjects seronegative for HPV16 as well as those seronegative for all tested
HPV types (Table 4). Consistent with the previous analyses TMC8 genotype was inversely as-
sociated with HNSCC among those seronegative for HPV16 (ORAT = 0.67; 95% CI: 0.45–1.03;
ORTT = 0.58; 95% CI: 0.34–1.00); this relationship remained for those negative for all HPV
types (ORAT = 0.713; 95% CI: 0.45–1.11; ORTT = 0.54; 95% CI: 0.31–0.93). Subgroup analysis
restricted to those seropositive was not possible given the low prevalence of seropositivity
among controls (Table 1).
Table 2. Association between TMC8 genotype and HPV L1 seropositivity—all subjects.
TMC8 genotypea
HPV type AA AT TT ORAT vs AA (95% CI)
b ORTT vs AA (95% CI)
b
High risk
HPV16 25/176 45/350 14/165 0.91 (0.54–1.55) 0.58 (0.29–1.17)
HPV18 26/175 35/360 12/167 0.65 (0.38–1.11) 0.48 (0.24–0.99)
Other types
HPV11 13/188 25/370 14/165 0.98 (0.49–1.95) 1.23 (0.56–2.69)
HPV31 22/179 27/368 10/169 0.60 (0.33–1.09) 0.48 (0.22–1.04)
HPV33 8/193 11/384 5/174 0.70 (0.28–1.76) 0.69 (0.22–2.15)
HPV35 14/187 24/371 9/170 0.87 (0.44–1.73) 0.70 (0.30–1.66)
HPV45 10/191 16/379 4/175 0.82 (0.36–1.84) 0.43 (0.13–1.41)
HPV52 12/189 6/389 4/175 0.25 (0.09–0.67) 0.36 (0.11–1.13)
HPV58 10/191 10/385 6/173 0.51 (0.21–1.24) 0.66 (0.23–1.85)
a number of individuals L1 positive/L1 negative.
b All OR’s adjusted for sex and age.
doi:10.1371/journal.pone.0123716.t002
Table 3. Association between TMC8 genotype and risk of HNSCC.
All sites Oral cavity Pharynx Larynx
TMC8 genotype na ORb (95% CI) na ORb (95% CI) na ORb (95% CI) na ORb (95% CI)
AA 113/142 referent 113/64 referent 113/52 referent 113/26 referent
AT 278/212 0.63 278/83 0.56 278/91 0.69 278/38 0.64
(0.45–0.89) (0.36–0.87) (0.44–1.04) (0.34–1.21)
TT 144/88 0.54 144/31 0.42 144/41 0.60 144/16 0.49
(0.36–0.81) (0.24–0.73) (0.35–1.01) (0.23–1.07)
a cases/controls.
b All OR’s adjusted for sex, age, packyears smoked and average drinks per week.
doi:10.1371/journal.pone.0123716.t003
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Discussion
In our case-control study of head and neck cancers, we find evidence that genetic variation in
TMC8 is inversely associated with seropositivity to high-risk HPV types. Further, TMC8 vari-
ant genotype is inversely associated with risk of HNSCC, independent of anatomic location,
and independent of HPV status.
Previously, we reported that this same genetic variation in TMC8 was positively associated
with cutaneous-type HPV infection [2]. At first glance, these strikingly different results be-
tween HPV types are surprising. However, if we consider the structural differences in the alpha
and beta HPV genomes, a model emerges based on the viral E5 protein. One important differ-
ence between cutaneous (beta) HPVs and high-risk (alpha) types is presence of the E5 protein.
In high-risk HPV, the E5 protein directly binds to the EVER/ZnT-1 complex [15]. As Larzarc-
zyk explains, the EVER/ZnT-1 complex is a restriction point for HPV infection whereby alter-
ation of this complex (and its subsequent dysregulation of zinc) is necessary for infection to
occur [1]. It is plausible that the TMC8 polymorphism alters the binding potential of the HPV
E5 protein to the EVER/ZnT-1 complex, and this lessens the probability of a productive HPV
infection. In contrast, the cutaneous type HPVs do not rely on E5 for productive infection (as
the cutaneous HPV genome is devoid of E5). Gaud et al have demonstrated that the TMC8
polymorphism alters the ability of EVER2 to interact with TRADD, thereby altering apoptosis
potential [16]. We hypothesize that the common genetic variation in TMC8 influences HPV
susceptibility by two different mechanisms, dependent on the presence of absence of the E5
protein. In vitro experiments will be necessary to definitively answer these questions.
While EVER2 expression in keratinocytes has received considerable attention, given its role
in the inherited syndrome Epidermodysplasia Verruciformis, recent work demonstrates that
EVER2 expression in T lymphocytes exceeds that found in keratinocytes. In T-cells this high
expression of EVER2 is rapidly down-regulated upon TCR stimulation, leading to an increase
in intracellular Zn levels. We hypothesize that the TMC8 polymorphism modulates this biolo-
gy, impacting T-cell surveillance functions and cancer risk. Additional epidemiologic studies of
non-viral mediated cancers will help elucidate whether TMC8 is a generalized cancer
susceptibility factor.
There are several limitations to the data in this study. The serologic endpoint used is highly
specific for a high-risk HPV infection. However, it must be noted that serology as an endpoint
has limited sensitivity, as not all individuals mount a serologic response with HPV infection. In
the context of our hypothesis concerning TMC8 genotype and susceptibility to infection, this
potential limitation in sensitivity would bias our results to the null. Another limitation of these
data is that the serologic response we assess is not necessarily reflective of an infection at the
tumor site, but might instead reflect a high-risk infection at a site other than the tumor. How-
ever, the low seroprevalence of high-risk HPV among non-diseased individuals (Table 1)
Table 4. Odds ratios for HNSCC and TMC8 genotype among seronegative individuals.
Seronegative for HPV16 Seronegative for all HPV types
TMC8 genotype na ORb (95% CI) na ORb (95% CI)
AA 83/84 referent 72/68 referent
AT 128/197 0.67 (0.43–1.03) 121/180 0.71 (0.45–1.11)
TT 49/100 0.58 (0.34–1.00) 46/94 0.54 (0.31–0.93)
a cases/controls.
b OR’s adjusted for sex, age, packyears smoked and average drinks per week.
doi:10.1371/journal.pone.0123716.t004
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indicates this is likely not a large misclassification problem. Finally, because of this low sero-
prevalence of the high-risk HPV types in our control population we are unable to test whether
TMC8 genotype is associated with infection in non-diseased individuals, and this will be im-
portant to address in future work.
Of interest, a previous study of cervical cancer by Wang et al, using a GWAS approach,
identified a rare SNP in the TMC6/8 region as associated with HPV16 viral persistence
(rs9893818, A allele frequency 2.5%) [5], indicating that genetic variation beyond the common
SNP presented here may be important for understanding HPV infection. A recent study by
Castro et al [6], reported two additional common SNPs in the TMC6/TMC8 gene were associ-
ated with cervical cancer, however this study lacked measures on HPV (although it would be
implied among cases). Clearly a comprehensive evaluation of the extent, character and pheno-
type of variation in the TMC6/TMC8 gene region will serve to more fully delineate our under-
standing of genetic susceptibility to HPV infection. Finally, given our very strong associations
between TMC8 genotype and HNSCC in those without evidence of HPV infection it will be im-
portant to establish whether the TMC8 gene is a generalized cancer susceptibility factor.
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